Skip to main content
Paul Feuerstadt, MD, Gastroenterology, Hamden, CT, Milford Hospital

PaulFeuerstadtMDFACG

Gastroenterology Hamden, CT

Attending Physician Gastroenterology Center of Connecticut

Dr. Feuerstadt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Feuerstadt's full profile

Already have an account?

Education & Training

  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Gastroenterology, 2007 - 2010
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 2004

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2010 - 2025
  • NY State Medical License
    NY State Medical License 2006 - 2025
  • FL State Medical License
    FL State Medical License 2014 - 2016
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Ischemic Bowel Disorders 
    AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/6/2018

Authored Content

  • C. Difficile Infection at DDW 2023May 2023

Press Mentions

  • VIDEO: Low Risk for Congestive Heart Failure Exacerbation with Zinplava for C. Difficile
    VIDEO: Low Risk for Congestive Heart Failure Exacerbation with Zinplava for C. DifficileMay 15th, 2023
  • Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023
    Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023
  • Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (Fecal Microbiota, Live – Jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
    Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (Fecal Microbiota, Live – Jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious DiseasesMay 3rd, 2023
  • Join now to see all

Professional Memberships

Hospital Affiliations